Exhibit 99.1

Corgenix Medical Corporation

Annual Shareholder Meeting

January 18, 2008

PowerPoint Presentation

Slide 1 — Title Slide

Annual Meeting of the Shareholders
January 18, 2011

Slide 2 — Agenda

·                  Review of Corporate Goals

·                  Review of Fiscal Year 2010

·                  Financials

·                  Key Events, Achievements and Disappointments

·                  Fiscal Year 2011 Goals

·                  Review of Fiscal Year 2011 Year-to-Date Results

·                  Financials

·                  Key Events, Achievements and Disappointments

·                  Plan for 2012-2014

Slide 3 — Corporate Goals

·                  Financial Strength

·                  Consistent Growth in Revenues and Profitability

·                  Broaden Product Base

·                  Improve Shareholder Liquidity

·                  Enhanced Product Quality and Regulatory Compliance

·                  New Customers and Strategic Partners

Slide 4 — FY 2009, 2010 and FY 2011 YTD Summary Statements of Operations

Slide 5 - FY 2009, 2010 and FY 2011 Summary Balance Sheets

Slide 6 — FY 2010 — Key Events of the Year

·                  October 2009

·                  Secured new credit facility of $1.75 million

·                  AMA established  new reimbursement code (CPT) for Aspirin Works

·                  December 2009

·                  Supply agreement established with BG Medicine for their Galectin-3 ELISA product

·                  February 2010

·                  Corgenix and Tulane announce award of 3rd Lassa fever grant totaling $15.2 million — further enhances IVD program but also moves us into vaccines and therapeutics

·                  March 2010

·                  Announcement of launch of line of antiphospholipid products for automated systems

·                  June 2010

·                  Announced new European AtherOx patents bringing the total number of AtherOx patents issued to sis (6)

·                  Announced new US patent for AspirinWorks — patent on monoclonal antibody significantly strengthens company proprietary position

Slide 7 — FY 2010 Accomplishments

·                  Reached level of net profitability

·                  Demonstrated top line growth despite the lingering difficult market conditions

·                  Improvement in Cost of Goods Sold %

·                  10.7% reduction in operating expenses

·                  Operating income increased $650,000

·                  Interest expense decreased almost $1 million

·                  EBITDA doubled to $816,000

·                  Strengthened our patent position

·                  Major advancement in several important strategic programs

·                  Expanded international distribution network

·                  Prepared for ELITech alliance

Slide 8 — FY 2010 Disappointments

·                  Inability to break out of low $8 million revenue range

·                  AspirinWorks business growing but slower than original expectations

Slide 9 — FY 2011 Goals

·                  Generate more significant revenue growth

·                  Maintain improvement in operating income, EBITDA, and overall financial strength

·                  Continue building foundation of market for AspirinWorks and generate meaningful revenue

·                  Advance science of AtherOx and prepare for next FDA 510(k) filing

·                  Continue progress of viral program and launch first products

·                  Enhance contract manufacturing business with new strategic alliances

Slide 10 — FY 2011 YTD Key Events of the Year

·                  July 2010

·                  Announced the new affiliation with the ELITech Group

·                  January 2011

·                  US reimbursement rate of AspirinWorks increased by 28%

Slide 11 - FY 2011 YTD Accomplishments

·                  Completion and implementation of agreements with ELITech with minimal hiccups

·                  New investment capital (1st and 2nd tranches) closed

·                  Transfer of international distribution responsibilities

·                  Initiated development of new products

·                  Investigating long term collaboration opportunities

·                  Wind-down of Corgenix UK office

·                  AspirinWorks growth is beginning to ramp up

·                  Achieved increase in US reimbursement of AspirinWorks which will add additional energy to growth

·                  Q-1 demonstrated net profit (excluding UK exit costs)

Slide 12 — FY 2011 YTD Disappointments

·                  Restructuring consuming meaningful amount of management time and focus

·                  Slight dip in revenues in Q-1

Slide 13 — Plan for FY 2012-2014

·                  Return to double digit revenue growth via accelerated growth rate from new products and new distribution

·                  Expand contract manufacturing business with new strategic partners

·                  Achieve positive and continuously improving operating income and EBITDA

·                  Enhance shareholder value

·                  Build on strategic partnerships

·                  Maintain superior quality system to ensure full regulatory compliance

·                  Expand delivery technology capabilities